Thus, Bcl-2 inhibitors are able to overcome this form of imatinib resistance, suggesting a shift of oncogene addiction from BCR-ABL to Bcl-2 in these imatinib-resistant CML cells. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.